Active GMP Recombinant Human Activin A Protein

• Cat.No.: Activin A-01HG
• Product Overview: Recombinant human Activin A protein, was expressed in CHO-K1 cell-derived in an animal component free process under cGMP guidelines.

Specification

• Description: Activin (activins) Activin A is a secreted protein of the transforming growth factor (TGF) β family that controls the development of the embryonic axis into a functional prointestinal-derived tissue and mediates the growth and differentiation of a variety of cells. Various studies have shown that it induces the differentiation of pancreatic β-cells. It can exert more significant induction effects especially when combined with other factors. Inhibition of the activin signaling pathway can be applied to expand precursor cells, while activation of activin facilitates β-cell differentiation. These results suggest that the balance between pancreatic growth and differentiation can be achieved by the precise regulation of the activin signaling pathway. It has also been widely used in stem cell research to induce differentiated embryonic stem cells to form endoderm.
• Source: CHO-K1
• Species: Human
• Form: Lyophilized powder
• Endotoxin: <20 EU/mg
• Bio-activity: >5.0 x 10^4 IU/mg
• Purity: >95.0% by high performance liquid chromatography (SEC-HPLC) and SDS-PAGE.
• Storage Buffer: 10mM Phosphate-Buffered Saline (pH 7.2)
• Storage: Stable storage at 4℃ for 7-10 days; for long-term storage, please store at -20℃ after dispensing.
• Sterility: Sterility
• Stability: Avoid repeated freezing and thawing as much as possible.
• Instructions: It is recommended that lyophilized GMP recombinant human Activin A be dissolved in water for injection or sterilized ultrapure water at a concentration of not less than 100 μg/ml, pending further dilution to working concentration.

Reviews

12/30/2021

The protein product maintains remarkable consistency in its physical and biochemical properties, such as molecular weight, solubility, and activity, across multiple production lots.

09/28/2020

The protein product is shipped promptly, and we have consistently received our orders within the expected timeframe.

01/01/2019

The protein product exhibits exceptional purity, confirmed by rigorous analytical testing methods such as SDS-PAGE and mass spectrometry.

08/05/2016

In our experiments, the protein product consistently demonstrates potent and specific binding to its target, leading to robust biological effects.

06/04/2016

The company's customer support team is responsive, knowledgeable, and readily addresses any technical or scientific questions we have regarding the protein product.

Q&As

How does activin A modulate miRNA expression in PCa (prostate cancer) cell lines?

Activin A has the ability to modulate miRNA expression in PCa cell lines, suggesting a potential relationship between miRNA expression and downstream target genes.

How can serum activin A levels be measured?

Serum activin A levels can be measured using immunoassay techniques, such as enzyme-linked immunosorbent assays (ELISA) or radioimmunoassays (RIA).

How does activin A affect CD8+ T cells and CD19+ B cells in Kawasaki disease?

Activin A increases the expression of activin type IIA receptor on CD8+ T cells and CD19+ B cells in Kawasaki disease.

What is the association of activin A with TGF-β1, eosinophils, and RBM thickness in SRA?

The association suggests that activin A may play a role in the inflammatory and remodeling processes in SRA (systemic rheumatic autoimmune diseases).

Is the increase in myostatin and activin A plasma concentrations in CKD primarily due to increased production or decreased renal clearance?

While myostatin is not overproduced in CKD, suggesting impaired renal clearance, activin A is overproduced in the kidney and heart.

Can activin A serve as a biomarker for the incidence of DD and development of HF?

The association between enhanced serum activin A levels and the incidence of DD and development of HF suggests that activin A may serve as a potential biomarker for these conditions.

How do myostatin and activin A affect muscle metabolism and growth?

Myostatin and activin A negatively regulate muscle metabolism and growth by promoting muscle wasting and inhibiting muscle protein synthesis.

Are myostatin and activin A potential therapeutic targets for mitigating muscle wasting in CKD?

Based on their role in muscle wasting, myostatin and activin A may be potential therapeutic targets for addressing muscle loss in CKD.

How is activin A associated with myocardial fibrosis?

Activin A is implicated in myocardial fibrosis, indicating its potential involvement in the pathological remodeling of heart tissue.

What is the involvement of activin A in CCl4-induced acute liver injury?

Activin A has been shown to be involved in the pathogenesis of CCl4-induced acute liver injury.

What is the association between myostatin and activin A plasma concentrations in chronic kidney disease (CKD)?

In CKD, both myostatin and activin A plasma concentrations are increased.

What are the consequences of increased myostatin and activin A plasma concentrations in CKD?

ncreased myostatin and activin A plasma concentrations in CKD can contribute to muscle wasting and further impair muscle function and strength.

What role does activin A play in the inflammatory response?

Activin A is involved in the inflammatory response, suggesting its contribution to the regulation of immune and inflammatory processes.

What proposal is made regarding myostatin and activin A in relation to uremic toxins?

The proposal suggests adding myostatin and activin A to the list of uremic toxins, indicating their potential role in CKD-related complications.

Are enhanced serum activin A levels linked to specific health conditions?

Yes, enhanced serum activin A levels are associated with the incidence of DD (diastolic dysfunction) and the development of HF (heart failure).

How do myostatin and activin A influence the ubiquitin proteasome system and Akt/mTOR pathway?

 Myostatin and activin A activate the ubiquitin proteasome system, leading to increased protein degradation, and inhibit the Akt/mTOR pathway, which negatively affects muscle protein synthesis.

What therapeutic approach is suggested for acute liver injury based on the actions of activin A?

Blocking the actions of activin A is proposed as a potential therapeutic approach for acute liver injury.

Are there any therapeutic implications for targeting activin A in the context of inflammatory response and myocardial fibrosis?

Targeting activin A could potentially have therapeutic implications for mitigating the inflammatory response and reducing myocardial fibrosis, although further research is needed to explore this possibility.

How does activin A contribute to myocardial fibrosis?

The involvement of activin A in myocardial fibrosis suggests that it may play a role in the pathological accumulation of fibrous tissue in the heart.

What effect does activin A have on peripheral CD8+ T lymphocytes in acute-phase Kawasaki disease?

Activin A suppresses the expression of CD25, CD69, and activin type IIA receptors on peripheral CD8+ T lymphocytes, thereby reducing their activity.

How do myostatin and activin A contribute to muscle wasting?

Myostatin and activin A induce muscle wasting by activating the ubiquitin proteasome system, which leads to protein degradation, and by inhibiting the Akt/mammalian target of rapamycin (mTOR) pathway, which hinders muscle protein synthesis.